Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a Finnish company, which develops, manufactures and markets pharmaceuticals, active pharmaceutical ingredients and diagnostic tests for global markets. The company also has a large R&D unit in Turku.
ORION CORPORATION ...OrionCorporation ... and its funds decreased on 20 March 2025 below five (5) per cent of Orion Corporation's total shares ... Orion Corporation Liisa Hurme ... Tuukka Hirvonen, Investor Relations, Orion Corporation ... Orion Corporation.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
OrionCorporation has received the following disclosure under MarketAbuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion is positioning itself to supply metals critical to the global clean energy transition, targeting first production from its key projects in 2026 ... Orion said it has made significant progress on its PrieskaCopperZincMine (PCZM) development.
OrionCorporation today announced that it is establishing a new research & development centre in Cambridge, UK during 2025 to accelerate its global growth strategy and the development of innovative medicines.